An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
- 2 December 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 21 (3) , 275-285
Abstract
Introduction: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervention should be the first line of management for obesity but additional pharmacotherapy is often required and bariatric surgery is appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM. Areas covered: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity. Expert opinion: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects. Like most of the other medications currently available for obesity, liraglutide has some common adverse effects, although generally not serious ones. Liraglutide has additional benefits in reducing cardiovascular events in patients with T2DM but the cost and the need for daily injections may limit its use in obesity. Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide.Keywords
This publication has 77 references indexed in Scilit:
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue LiraglutideThe Journal of Clinical Pharmacology, 2011
- Liraglutide for type 2 diabetes mellitusExpert Opinion on Biological Therapy, 2011
- Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutideBritish Journal of Clinical Pharmacology, 2010
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsNew England Journal of Medicine, 2010
- Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutideBritish Journal of Clinical Pharmacology, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006